Voclosporin
Brand names: Lupkynis
Voclosporin is a calcineurin-inhibitor immunosuppressant used, in combination with other therapy, to treat active lupus nephritis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits calcineurin to suppress T-cell activation and cytokine production, and stabilises the podocyte cytoskeleton, reducing proteinuria.
Prescribing in practice
- Voclosporin is nephrotoxic and can raise blood pressure, so renal function and blood pressure must be monitored and the drug avoided or adjusted if eGFR falls significantly.
- It is metabolised by CYP3A4, so combination with strong CYP3A4 inhibitors is contraindicated and other interacting drugs require review per the SPC.
- Monitor for hyperkalaemia, QT considerations and infection, and use established immunosuppression precautions including infection screening.
Monitoring
Monitor renal function, blood pressure, serum potassium and signs of infection throughout treatment.
Counselling the patient
- Avoid grapefruit and tell your clinician about all other medicines you take.
- Attend for blood-pressure and kidney monitoring, and report any signs of infection.
Evidence & guidelines
Voclosporin added to standard therapy improved renal response in lupus nephritis in the randomised AURORA trial programme.
Reference: NICE TA882; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022